[Skip to Content]
[Skip to Content Landing]
January 28, 1974

Sex, Splenectomy, and Myeloid Metaplasia

Author Affiliations

From the Division of Hematology and Internal Medicine (Dr. Silverstein) and the Department of Surgery (Dr. ReMine), Mayo Clinic, Rochester, Minn.

JAMA. 1974;227(4):424-425. doi:10.1001/jama.1974.03230170040012

Over the last decade, 29 patients with agnogenic myeloid metaplasia had splenectomies. Indications for splenectomy included hemolytic anemia, thrombocytopenia, mechanical splenomegaly, and portal hypertension. The 13 women tended to be younger when splenectomized, had a longer duration of illness before splenectomy, and had the procedure for pressure symptoms, thrombocytopenia, or portal hypertension.

Fifty percent of the men had serious postoperative complications, compared with only 23% of the women; 50% of the women survived at least five years after the procedure, whereas only two men are living two years after the procedure, and 14 have died within an average of two years after splenectomy.